

**IMAGIN MEDICAL INC.**  
**MANAGEMENT DISCUSSION & ANALYSIS**

**For the Three Months Ended December 31, 2020**

**Directors and Officers as of February 25, 2021**

**Directors:**

Robin Atlas  
Chris Bleck  
Ken Daignault  
Jim Hutchens  
John Vacha

**Officers:**

President & C.E.O. – Jim Hutchens  
C.F.O. & Secretary – John Vacha

**Contact Names:**

Jim Hutchens  
John Vacha

**Telephone Number:**

833-246-2446

**IMAGIN MEDICAL INC.**

**MANAGEMENT DISCUSSION & ANALYSIS**

For the Three Months Ended December 31, 2020

**1.1 Date of This Report**

**February 25, 2021**

This Management's Discussion & Analysis ("MD&A") of Imagin Medical Inc. for the three months ended December 31, 2020 has been prepared based on information available to us as of February 25, 2021. This discussion should be read in conjunction with the Condensed Interim Consolidated Financial Statements of the Company and notes attached thereto for the three months ended December 31, 2020 included herewith, all of which are available at the SEDAR website at [www.sedar.com](http://www.sedar.com).

*This MD&A includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include product development timing, government regulatory approvals, hospital reimbursement, continued availability of capital and financing and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Reported currency is stated in Canadian dollars.*

**1.2 Overall Performance**

***Description of Business***

Imagin Medical Inc. (formerly Expedition Mining Inc.) is incorporated in the Province of British Columbia. On February 9, 2016, the Company completed the acquisition of BSS Life Sciences Inc. ("BSS"). BSS holds the intellectual property rights to a proprietary imaging technology developed for extremely accurate visualization of cancers. In connection with the acquisition, the Company changed its name to Imagin Medical Inc. and now focuses on research, development and commercialization in the device/instrumentation medical technology industry.

***License Agreement***

By way of a Licence Agreement dated May 20, 2015, BSS was granted an exclusive, nontransferable, royalty-bearing license by Lawrence Livermore National Security, LLC (LLNS), to use LLNS's patents and intellectual property rights to manufacture and sell products and services pertaining to *in vivo* imaging applications.

Under the License Agreement, BSS must:

- complete a commercial prototype by December 31, 2016 (first prototype completed);
- complete submissions for United States Food and Drug Administration (“FDA”) approval by September 30, 2021.
- achieve first commercial sales (“FCS”) in the United States within one year of achieving the FDA approval; and
- achieve gross cumulative sales revenues from the sales of licensed products of at least \$10,000,000 within the first three years of achieving FCS.

The sales requirements may be amended and/or extended at the written request of BSS to LLNS, based upon legitimate business reasons specified in reasonable detail in such written request.

BSS must pay certain fees to LLNS for the licence, being (all amounts are in US dollars):

- (i) a nonrefundable issue fee of \$100,000 payable as follows:
  - \$10,000 upon the date of execution of the Agreement (June 22, 2015; paid);
  - \$30,000 by November 22, 2015 (paid);
  - \$30,000 by January 22, 2016 (paid); and
  - \$30,000 by March 22, 2016 (paid).
- (ii) an earned royalty of 3% of net sales, subject to minimum annual royalties of:

Calendar year	Minimum annual royalty	Due date
2017	\$5,000	February 28, 2017 (paid)
2018	\$10,000	February 28, 2018 (paid)
2019	\$10,000	February 28, 2019 (paid)
2020	\$25,000	February 28, 2020 (paid)
2021	\$5,000	February 28, 2021
2022	\$5,000	February 28, 2022
2023	\$5,000	February 28, 2023
2024 and thereafter	\$25,000	February 28, 2024

- (iii) a nonrefundable U.S. Maintenance Patent Fee of \$45,000 to be paid as follows:
  - \$15,000 on or before February 28, 2016 (paid);
  - \$15,000 on or before February 28, 2019 (paid); and
  - \$15,000 on or before February 28, 2023

### ***The Technology***

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries (MIS). The Company’s first

product, the i/Blue Imaging™ System, is based on advanced optics and light sensors and employs patented ultrasensitive imaging technology. The Company believes the i/Blue System, with easy-to-use imaging options, will significantly improve surgeons' ability to visualize cancerous cells for more accurate resection. The Company's initial focus is bladder cancer.

The i/Blue Imaging System is a device external to the body that attaches to an endoscope to emit both white and blue light during MIS. When used in combination with contrast agents, cancerous cells, including premalignant lesions and tumor tissue along the margins, begin to fluoresce within an hour or less. The i/Blue Imaging System provides the option to display, in real-time, the white and blue light images side-by-side. This advancement eliminates the surgeon's need to switch back and forth between the white and blue light images when locating and then resecting the cancer as needed with current technology.

Imagin's i/Blue Imaging System is comprised of two key, state-of-the-art components:

- The i/Blue Control Unit: contains a dual wave-length light source, a two-channel camera control unit, data recorder and power supply modules that allow simultaneous displays of white and blue light illumination in the interior of the bladder.
- Dual View Camera Handpiece: includes sophisticated optical filters that split the image into white and blue light channels, allowing simultaneous display of corresponding images on the surgical monitor. This patented technology compatible with most endoscopes on the market today and offers multiple real-time viewing options/images that better enable the surgeon to visualize and resect the cancer.

#### *Benefits of the i/Blue Imaging System*

- Simultaneous side-by-side white and blue light images
- No toggling back and forth between images
- Shows cancer in context within the bladder
- Enables surgeons to better visualize cancerous cells for more accurate resection
- Compatible with most endoscopes on the market
- Appropriate for physicians' offices

#### *Future Development - Disruptive Technology /Multiple Markets*

Imagin intends to build on the i/Blue technology, which currently works with hexaminolevulinate hydrochloride (HAL), and adapt it to other U.S. Food and Drug Administration (FDA) approved contrast agents, such as Indocyanine green (ICG). These additional products will expand Imagin's market potential, facilitating entry into multiple endoscopic procedures, such as laparoscopic (general and gynecology), colorectal and thoracic.

Imagin is actively pursuing opportunities to acquire or distribute additional products such as disposable scopes, cancer biopsy devices and other products to complement its portfolio.

## ***The Strategy***

Imagin Medical will differentiate the bladder cancer imaging market by improving surgical technique that will lead to improved resections. This will be accomplished by the providing white and blue light images simultaneously, side-by-side on the monitor. Additionally, Imagin will be the low-cost producer and allow the company to make significant margin yet price the i/Blue System at a significant discount from current products.

Imagin's original timeline for the coming year has been revised to accommodate the impact of Covid-19. The Company remains deeply committed to advancing the i/Blue Imaging System toward commercialization.

Imagin will continue to strengthen relationships with urologists and key opinion leaders, as well as engage in market development activities through virtual meeting, events, and demonstrations over the coming months. An example of this was the successful webinar showcasing the i/Blue Imaging System, interviews and commentary from leading urologists, and a financial analyst from CNBC regarding the on-going excitement in the healthcare environment. It remains Imagin's plan to differentiate the MIS surgical imaging market by focusing on state-of-the-art, easy-to-use, practical and cost-effective cancer visualization systems.

Once the i/Blue Imaging System is commercially available for urological indications, Imagin will focus on expanding the product platform from bladder cancer to laparoscopic (abdominal), colorectal, thoracic and other medical procedures. The Company will partner with manufacturers of contrast agents that are already FDA-approved or in their final phase (Phase III) of FDA approval.

The Company continues to plan for commercialization via initial marketing programs, future participation in trade shows and focus groups with key opinion leaders, along with the development of physician champions and Centers of Excellence. The Company will build on current relationships with key independent sales representatives currently successful in the urology marketplace.

Imagin plans to add complementary products to expand its product portfolio. Because the i/Blue technology is adaptable to most endoscopes currently on the market, the Company will be of strategic interest to existing dominant endoscope manufacturers.

## ***Intellectual Property***

The Company, through its wholly owned subsidiary (BSS Life Sciences) has secured an exclusive license from Lawrence Livermore National Security, LLC (LLNS) to commercialize the technology invented by Dr. Stavros Demos. This license agreement includes three issued patents and one pending patent application on technology related to exclusive spectroscopic imaging for cancer and other medical applications. These include:

1. Issued U.S. Patent 7,149,567 - Near-Infrared Spectroscopic Tissue Imaging for Medical Applications.

2. Issued U.S. Patent 7,257,437 - Autofluorescence Detection and Imaging of Bladder Cancer Realized Through a Cystoscope.
3. Issued U.S. Patent 8,285,015 - Simultaneous Acquisition of Differing Image Types.
4. Issued U.S. Patent 10,182,708 - Simultaneous Acquisition of Differing Image Types.

Based on product refinement and development since the completion of the University of Rochester study, Imagin intends to file additional patent that the Company anticipates will broaden its intellectual property portfolio.

### ***Product Development and Regulatory Approval***

The Company decreased non-essential expenses in all areas of its business to further extend Imagin's cash flow into the Fall of 2020. Cost cutting measures, including company-wide salary reductions, have been implemented, as well as precautionary measures such as sheltering in place and working from home, freezing travel, and switching to virtual development and operational meetings. These measures will remain in place as the current global situation remains uncertain.

Imagin Medical, as well as our partners, supply channels and consultants, have continued to be affected by the current pandemic. This affected our timeline by approximately nine months, which moves our product launch into 2022. We continue to evaluate operations as the situation evolves.

The i/Blue System has successfully transitioned from the development stage to manufacturing with Lighthouse Imaging, who will finalize the product design, move to pre-production units and pilot builds prior to commercialization. Lighthouse will provide proper documentation, as well as key device performance characteristics that have met technical design specifications using various testing techniques including, but not limited to, analytic design calculations, measurements of physical characteristics and testing by independent laboratories. Data from these independent lab tests is being combined with data from internal testing, engineering calculations, component suppliers and competitive device analysis, all of which will become the basis of the Company's documentation requirements and will be included with Imagin's FDA submission.

Two i/Blue units were initially slated for a first-in-human study. However, medical institutions have suspended all medical device clinical studies due to the COVID-19 pandemic. Imagin will continue to pursue first-in-human studies when clinical trials are allowed to resume. Additionally, the Company will pursue animal studies as an alternative, if appropriate. The remaining functional units will be used for virtual investor and medical professional presentations and demonstrations.

Imagin believes that the imaging quality and cost reduction goals for the i/Blue Imaging System will be achieved. The product will be highly manufacturable and cost effective, with a modular design that will become a basic platform for Imagin's current and future imaging systems and applications.

As previously reported, the Company met with the FDA twice to proactively discuss the i/Blue Imaging System's regulatory path and the potential need for a clinical study. The content and feedback from the meeting are instrumental as the Company continues to refine its regulatory strategy and complete the formal FDA submission. Imagin will ensure that the i/Blue Imaging System will be in compliance with the requirements of the FDA's Quality System Regulation, ISO 13485:2016, Medical devices - Quality management systems - Requirements for regulatory purposes, and additional international compliance requirements.

### ***Highlights from Oct 1, 2019 up to the date of this report***

The Company announced the following:

- Announced that it closed the second tranche in the amount of US\$1,415,500 of the Convertible Note Offering.
- Announced that it has engaged San Diego Torrey Hills Capital, Inc. ("Torrey Hills Capital"), a Rancho Santa Fe, California based investor relations firm, to provide market awareness and investor relations services to the Company.
- Announced that critical milestones met in the second half of 2020 will support the Company in achieving its 2021 goals.
- Announced it had closed US\$750,000 (Tranche 1) of the US\$3,000,000 principal amount convertible notes.
- Announced the Company's intention to offer up to \$3,000,000 aggregate principal amount of Convertible Notes and undertake a twenty (20) to one (1) share consolidation subject to CSE approval. Please see Subsequent Events at the end of this Report.
- announced that it has selected Lighthouse Imaging ("Lighthouse") as the contract manufacturer for the Company's i/Blue Imaging System.
- announced that it will begin testing the i/Blue<sup>TM</sup> Imaging System using anatomical bladder models to confirm simultaneous white and blue light image display.

As at the date of this report, the Company reported a share structure as follows:

- Issued and Outstanding – 9,067,186
- Options granted – 635,000
- Finance warrants – 7,327,750
- Finder's warrants – 52,790

### **1.3 Selected Annual Information**

The highlights of financial data for the Company for the two most recently completed financial years are as follows:

	<u>Sept. 30, 2020</u>	<u>Sept. 30, 2019</u>
(a) Loss before other items		
(i) Total loss	\$4,352,095	\$4,499,927
(ii) Loss per share – basic	\$0.53	\$0.65
(iii) Loss per share – diluted	\$0.53	\$0.65
(b) Net loss		
(i) Total loss	\$4,376,849	\$4,457,322

(ii) Loss per share – basic	\$0.53	\$0.64
(iii) Loss per share – diluted	\$0.53	\$0.64
(c) Total assets	\$219,400	\$2,494,573

Loss per share was calculated using the post-consolidated weighted average of 8,297,096 in year end 2020 and 6,947,138 in year end 2019.

## 1.4 **Results of Operations**

### *Discussion of Operations and Financial Condition*

The following should be read in conjunction with the condensed interim consolidated financial statements for the three months ended December 31, 2020 and notes attached hereto.

During the three months ended December 31, 2020, the Company reported a net loss of \$562,260 (December 31, 2019 – \$1,241,659). The Company incurred the following major expenditures:

1. Business Development – \$Nil (December 31, 2019 – \$17,967) decreased by \$17,967. Business Development expenses were intentionally reduced because of Covid, which halted associated travel and in-person meetings.
2. Consulting fees – Total \$42,144 (December 31, 2019 – \$64,291) decreased by \$22,147. Consulting fees consists of:
  - Marketing and Investor Relations – \$33,078 (December 31, 2019 – \$47,428) decreased by \$14,350. In the previous year, the Company engaged numerous consultants to provide services primarily related to raising capital and public relations, specifically, internet marketing, research reports, news and press releases and their distribution. The Company continues with its ongoing communications and marketing programs to efficiently increase awareness of the progress of the Company, allowing the Company to continue to maintain its existing cash for product development and commercialization. However, in the current year, there have been no specific expenses related to the raising of capital which is the primary reason for the decrease from the prior period.
  - Sales & Marketing – \$3,857 (December 31, 2019 – \$11,830) decreased by \$7,973. The Company engaged consultants to provide services related to customer feedback and marketing.
  - OTC Listing – \$5,208 (December 31, 2019 – \$5,033) increased by \$175.
3. Legal & accounting – Total \$104,138 (December 31, 2019 – \$94,318) increased by \$9,820. The increase is related to legal fees incurred in connection with the convertible debt.
4. Management fees – Total \$146,476 (December 31, 2019 – \$148,601), paid Cdn\$98,177; unpaid Cdn\$42,299. The increase of \$2,125 is related to foreign exchange as the fees paid to the CEO is in US\$.
5. Product Development – Total \$208,894 (December 31, 2019 – \$639,178); decreased by \$430,284. These expenses are primarily related to the work performed by



outsourced design and engineering, regulatory, FDA, legal and quality consultants for the design and development of the i/Blue system and associated FDA & regulatory plans.

6. Shareholders' communication and promotion – Total \$94,356 (December 31, 2019 – \$228,456) decreased by \$134,100. The decrease is due to work performed by consultants related to shareholder communication and public relations, specifically, internet marketing, research reports, news and press releases and their distribution. Please refer to the table under “Shareholders Communication and Travel.”

The Company also reported receivables and prepaids for a total amount of \$393,184 (September 30, 2020 – \$46,200). The amount is broken down as follows:

		<b>31-Dec-20</b>	<b>30-Sep-20</b>
GST Receivable	\$	2,363	2,325
Trust account		1,100	-
Prepaid expenses *		389,721	43,875
	\$	<b>393,184</b>	<b>46,200</b>

\* The Company was billed in advance for services ranging from six months to a year with respect to services primarily related to raising capital and public relations. In addition, the Company had to make a deposit of US\$275,000 (Cdn\$357,972) to Lighthouse Imaging, the contract manufacturer for the Company's i/Blue Imaging System.

### **Shareholders Communication and Travel**

For the three months ended December 31, 2020, the Company reported shareholder communication and travel expenses totaling \$94,356 (December 31, 2019 – \$228,456) and is broken down as follows:

		<b>31-Dec-20</b>		<b>31-Dec-19</b>
Communication & information	\$	76,132	\$	178,339
Conferences		9,915		1,769
Press releases		-		7,461
Telephone & website		1,222		610
Travel & entertainment		7,087		40,277
	\$	<b>94,356</b>	\$	<b>228,456</b>

Communication & information expenses relate to an increase in investor outreach to promote investor awareness of the progress the Company has made towards bringing the i/Blue System to market. This included digital marketing campaigns, technical articles and investor outreach.

### **Summary of Quarterly Results**

The following is a summary of the Company's financial results for the eight most recently completed quarters:

	<b><u>Q1 31-Dec-20</u></b>	<b><u>Q4 30-Sep-20</u></b>	<b><u>Q3 30-Jun-20</u></b>	<b><u>Q2 31-Mar-20</u></b>
	<b>IFRS</b>	<b>IFRS</b>	<b>IFRS</b>	<b>IFRS</b>
Net loss	(562,260)	(689,057)	(582,805)	(1,744,702)
Per Share	(0.06)	(0.08)	(0.07)	(0.21)
	<b><u>Q1 31-Dec-19</u></b>	<b><u>Q4 30-Sep-19</u></b>	<b><u>Q3 30-Jun-19</u></b>	<b><u>Q2 31-Mar-19</u></b>
	<b>IFRS</b>	<b>IFRS</b>	<b>IFRS</b>	<b>IFRS</b>
Net loss	(1,241,659)	(1,318,105)	(1,201,561)	(926,070)
Per Share	(0.18)	(0.19)	(0.17)	(0.13)

Loss per share was calculated using the post-consolidated weighted average for the above eight quarters.

### ***Discussion***

#### **Three months ended December 31, 2020:**

For the three months ended December 31, 2020, please refer to Section 1.4 Results of Operations.

## **1.5 Liquidity**

The Company has no current operating income or cash flow. In management's view, given the nature of the Company's operations, the most relevant financial information relates primarily to current liquidity, solvency and planned expenditures. The Company's financial success will be dependent on continuing to raise operating capital and successful clinical trials that validate the Company's technology. Such activities may take time to complete and the amount of resulting income is difficult to determine.

On October 22, 2020, the Company announced an offering of up to \$3,000,000 aggregate principal amount of Convertible Notes and undertake a twenty (20) to one (1) share consolidation subject to CSE approval. The Notes are secured obligations of the Company, accrue 10% interest annually (payable semi-annually in arrears) and will mature 18 months following the date of issue (unless earlier repurchased, redeemed or converted). The Notes will be convertible at the holder's discretion into commons shares at a conversion price of US\$0.40 per share.

The Company closed the first tranche in the amount of US\$750,000. In conjunction with the Notes, the holders were issued 937,500 warrants (with each warrant entitling the holder to acquire a common share at US\$0.50) and 937,500 warrants (with each warrant entitling the holder to acquire a common share at US\$0.60). All warrants will be exercisable for five years from the date of issue.

On November 5, 2020, one of the note holders converted US\$20,000, plus accrued interest of US\$71. The Company issued 50,178 shares at US\$0.40 (Canadian \$0.522) per share. The Company recorded the transaction as Cdn\$26,377 using the foreign exchange rate at conversion date.

Subsequent to the period ended December 31, 2020, the Company closed the second tranche of the Convertible Note in the amount of US\$1,415,500. As per terms of the Convertible Note, the Company issued 1,769,375 warrants @ US\$0.50 and 1,769,375 @ US\$0.60. One of the note holders converted US\$40,000 to common shares, resulting in the issuance of 100,000 shares. The Company recorded the transaction as Cdn\$49,807 using the exchange rate at conversion date.

As at December 31, 2020, the Company had \$54,475 in cash and \$393,184 in accounts receivable and prepaid expenses. The Company currently has no revenue being generated from its i/Blue system for the early detection of cancer.

The Company's historical capital needs have been met by equity subscriptions. On December 31, 2020, the Company had a negative working capital of \$151,673 (September 30, 2020 -\$476,321 negative working capital).

#### Cash and cash equivalents

	31-Dec-20	30-Sep-20
Cash deposits	\$ 54,475	\$ 27,618
Guaranteed investment certificate	-	-
Total cash and cash equivalents	<b>\$ 54,475</b>	<b>\$ 27,618</b>

#### Credit Risk

Credit risk arises from cash held with banks and financial institutions. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The Company's cash is held with Canadian and US banks.

#### Currency Risk

Currency risk is the risk to the Company's earnings that arises from fluctuations of foreign exchange rates and the degree of volatility of these rates. The Company faces certain foreign exchange risks related to expenses incurred in U.S. dollars, a currency which may appreciate against the Canadian dollar, the Company's reporting currency. Additionally, net working capital balances denominated in non-reporting currencies are also subject to fluctuations in value. The Company mitigates these threats by limiting its exposure to such balances where their expenditure in the same non-reporting currency is not imminent.

#### Commitments

The Company has certain commitments related to the license agreement with Lawrence Livermore National Security. Please refer to Sections 1.2 Overall Performance – License Agreement.

### **1.6 Capital Resources**

The Company has no capital resources.

### **1.7 Off Balance Sheet Arrangements**

There are no off-balance sheet arrangements to which the Company is committed.

## 1.8 First Quarter

With the exception of the accounting presentation of the convertible notes, the first quarter result does not differ significantly from other quarters.

## 1.9 Transactions with Related Parties

During the three ended December 31, 2020, the Company paid and/or accrued \$224,265 (December 31, 2019 – \$243,427) to directors and officers or companies controlled by directors and officers of the Company, for management, accounting, and directors' fees incurred by the Company.

		31-Dec-20	31-Dec-19
Management fees	\$	146,476	148,601
Accounting fees		73,289	74,129
Consulting fees		-	17,697
Directors fees		4,500	3,000
<b>Total</b>	<b>\$</b>	<b>224,265</b>	<b>243,427</b>

- (i) With respect to the management fees of \$146,476, only \$98,177 was paid and the balance of \$48,299 remains unpaid;
- (ii) With respect to the accounting fees of \$73,289, only \$62,084 was paid and the balance of \$11,205 remains unpaid;
- (iii) The directors' fees of \$4,500 remain unpaid.

Included in accounts payable as at December 31, 2020 are fees due to directors and officers in the amount of \$246,237 (September 30, 2019 – \$236,960), which are non-interest bearing, unsecured, and payable on demand. Fair value cannot be reliably determined.

During the three months ended December 31, 2020 and 2019, the Company did not grant any stock options to directors and officers.

## 1.10 Proposed Transactions

N/A

## 1.11 Critical Accounting Estimates

In preparing financial statements, management has to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Based on historical experience, current conditions and expert advice, management makes assumptions that are believed to be reasonable under the circumstances. These estimates and assumptions form the basis for judgments about the carrying value of assets and liabilities and reported amounts for revenues and expenses. Different assumptions would result in different estimates and actual results may differ from results based on these estimates. These estimates and assumptions are also affected by management's application of accounting policies. Critical accounting estimates are those that affect the consolidated financial statements materially and involve a significant level of judgment by management.

## **1.12 Financial and Other Instruments**

The carrying value of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and due from (to) related parties approximate their fair values due to the short maturity of those instruments.

## **1.13 Other**

As of the date of this report, the Company reported the following:

Disclosure of Outstanding Share Capital:	
Common Shares	<u>9,067,186</u>
Disclosure of Outstanding Stock Options:	
Incentive Stock Options	<u>635,000</u>
Disclosure of Outstanding Share Purchase Warrants:	
Warrants	<u>7,380,540</u>
Fully diluted	<u>17,082,726</u>

### **Disclosure Controls and Procedures**

It should be noted that pursuant to Multilateral Instrument 52-511 (adopted by the British Columbia Securities Commission on November 23, 2007), that the officers of the Company are no longer required to certify the effectiveness of disclosure controls and procedures used by the Company, as was required in previous filings under National Instrument 52-109. Accordingly, the new forms of certificate to be signed by the Company's Chief Executive Officer and Chief Financial Officer contain the following Note to Reader:

In contrast to the certificate required under National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of:

- (i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- (ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

The issuer's certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate.

Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost-effective basis DC&P and ICFR as

defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of and annual filings and other reports provided under securities legislation.

### **Subsequent Events**

Subsequent to the end of the period, the following occurred:

- (i) Granted 100,000 employee stock options with an exercise price of \$0.62, fully vested and expiring in three years.
- (ii) 60,000 employee stock options with an exercise price of \$3.00 per option expired, unexercised.
- (iii) Closed Tranche 2 of the previously announced Convertible Note in the amount of US\$1,415,500.
- (iv) As per terms of the Convertible Note, issued 1,769,375 warrants at US\$0.50 and 1,736,375 warrants at US\$0.60.
- (v) One of the lenders from Tranche 2 converted US\$40,000 to common shares resulting in the issuance of 100,000 shares.

Additional information relating to the Company is on SEDAR at [www.sedar.com](http://www.sedar.com).